On the Use of Change in Tumor Size to Predict Survival in Clinical Oncology Studies:Toward a New Paradigm to Design and Evaluate Phase II Studies

摘要：

Drug-independent models that link biomarker response to clinical end points are critical to support early (end of phase II) clinical decisions.In oncology,change in tumor size (a biomarker of drug effect evaluated in phase II) is linked to survival (a phase III end point) in some solid tumors.Change in tumor size can be used as a primary end point in the design and evaluation of phase II studies and in supporting go/no-go decisions and phase III study design.

作者: R Bruno L Claret

作者单位: Pharsight,Munich,Germany

会议类型: 国际会议

会议名称: 21st International Conference on Screening for Lung Cancer(第21届国际肺癌筛查大会)

会议地点: 珠海

会议语种:英文

页码: 77-79

在线出版日期: 2009-10-01（万方平台首次上网日期，不代表论文的发表时间）